Commerzbank Aktiengesellschaft FI Purchases 2,608 Shares of Boston Scientific Corporation (NYSE:BSX)

Commerzbank Aktiengesellschaft FI boosted its stake in Boston Scientific Corporation (NYSE:BSX - Free Report) by 19.8% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 15,763 shares of the medical equipment provider's stock after purchasing an additional 2,608 shares during the quarter. Commerzbank Aktiengesellschaft FI's holdings in Boston Scientific were worth $1,590,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of BSX. Norges Bank acquired a new position in shares of Boston Scientific during the fourth quarter worth about $1,762,522,000. Capital World Investors lifted its position in shares of Boston Scientific by 28.7% in the fourth quarter. Capital World Investors now owns 27,899,903 shares of the medical equipment provider's stock valued at $2,492,041,000 after buying an additional 6,216,199 shares during the last quarter. Wellington Management Group LLP lifted its position in shares of Boston Scientific by 10.2% in the fourth quarter. Wellington Management Group LLP now owns 36,165,399 shares of the medical equipment provider's stock valued at $3,230,293,000 after buying an additional 3,344,571 shares during the last quarter. GAMMA Investing LLC increased its stake in shares of Boston Scientific by 11,720.3% during the first quarter. GAMMA Investing LLC now owns 2,577,887 shares of the medical equipment provider's stock worth $260,057,000 after purchasing an additional 2,556,078 shares during the period. Finally, Axiom Investors LLC DE increased its stake in shares of Boston Scientific by 208.2% during the fourth quarter. Axiom Investors LLC DE now owns 3,752,430 shares of the medical equipment provider's stock worth $335,167,000 after purchasing an additional 2,535,007 shares during the period. 89.07% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

BSX has been the topic of a number of recent research reports. Robert W. Baird increased their target price on Boston Scientific from $115.00 to $120.00 and gave the stock an "outperform" rating in a research note on Thursday, April 24th. Morgan Stanley raised their target price on Boston Scientific from $120.00 to $125.00 and gave the company an "overweight" rating in a report on Friday, May 16th. Needham & Company LLC reissued a "buy" rating and set a $115.00 price objective on shares of Boston Scientific in a report on Wednesday, May 28th. Wall Street Zen raised Boston Scientific from a "hold" rating to a "buy" rating in a report on Tuesday, April 29th. Finally, Leerink Partnrs raised Boston Scientific to a "strong-buy" rating in a report on Monday, June 16th. Twenty-two analysts have rated the stock with a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Buy" and an average target price of $116.09.

Insider Transactions at Boston Scientific

In other news, CEO Michael F. Mahoney sold 164,443 shares of the business's stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $103.69, for a total value of $17,051,094.67. Following the transaction, the chief executive officer owned 1,476,882 shares in the company, valued at $153,137,894.58. The trade was a 10.02% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Arthur C. Butcher sold 17,314 shares of the company's stock in a transaction that occurred on Thursday, May 1st. The shares were sold at an average price of $102.06, for a total value of $1,767,066.84. Following the completion of the transaction, the executive vice president owned 22,235 shares in the company, valued at approximately $2,269,304.10. The trade was a 43.78% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 461,970 shares of company stock worth $47,755,193. 0.50% of the stock is owned by insiders.

Boston Scientific Stock Down 0.9%

Shares of Boston Scientific stock traded down $0.97 on Friday, hitting $103.68. The company had a trading volume of 8,571,099 shares, compared to its average volume of 6,759,200. Boston Scientific Corporation has a 1 year low of $71.88 and a 1 year high of $107.53. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.88 and a current ratio of 1.45. The stock has a 50 day moving average of $103.40 and a 200-day moving average of $100.90. The stock has a market capitalization of $153.39 billion, a price-to-earnings ratio of 75.68, a P/E/G ratio of 2.72 and a beta of 0.68.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating analysts' consensus estimates of $0.67 by $0.08. Boston Scientific had a return on equity of 18.67% and a net margin of 11.58%. The company had revenue of $4.66 billion for the quarter, compared to analyst estimates of $4.57 billion. During the same quarter last year, the company earned $0.56 earnings per share. The company's revenue for the quarter was up 20.9% on a year-over-year basis. As a group, sell-side analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.